secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-02-11T23:59:59+00:00
Accession:  0001178913-22-000575
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab shareholders approve CEO Dale Pfost as Chairman of the Board
---------------------------------------------------------------------

- Special meeting on Feb 10, 2022; 89,749,560 shares represented (~39.35% of outstanding).
- Shareholders voted to approve CEO Dr. Dale Pfost as Chairman of the Board.
- Vote results: 84,227,920 FOR, 5,510,320 AGAINST, 11,320 ABSTAIN.
- Requisite majority under Israeli Companies Law satisfied; non-controlling shareholder votes also approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322000575/0001178913-22-000575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322000575/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-000575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer